61 results on '"Antimyosin antibody"'
Search Results
2. Targeting the Pathological Myocardium
- Author
-
Khaw, Ban-An, Muzykantov, Vladimir, editor, and Torchilin, Vladimir, editor
- Published
- 2002
- Full Text
- View/download PDF
3. Strategies and Means for Drug Targeting: An Overview
- Author
-
Torchilin, Vladimir P., Muzykantov, Vladimir, editor, and Torchilin, Vladimir, editor
- Published
- 2002
- Full Text
- View/download PDF
4. Long Circulating Liposomes for Diagnostic Imaging
- Author
-
Trubetskoy, Vladimir S., Torchilin, Vladimir P., Woodle, Martin C., editor, and Storm, Gerrit, editor
- Published
- 1998
- Full Text
- View/download PDF
5. Recognition of Rhabdo- and Leiomyosarcomas by Means of in-111 Labeled Antimyosin-Antibody Fragments — An Improvement for the Oncologic Diagnostic
- Author
-
Franke, W.-G., Wiener, S., Weiß, S., Siegert, E., Köhler, K., Bergmann, Helmar, editor, and Sinzinger, Helmut, editor
- Published
- 1995
- Full Text
- View/download PDF
6. 111In-Antimyosin Antibodies for Detection of Heart Transplant Rejection
- Author
-
Carrió, I., Martin-Comin, J., editor, Thakur, M. L., editor, Piera, C., editor, Roca, M., editor, and Lomeña, F., editor
- Published
- 1994
- Full Text
- View/download PDF
7. Detection of Disruption of Sarcolemmal Membrane by Indium-111 Labeled Antimyosin Antibody Scan
- Author
-
Yasuda, T., Figulla, Hans-Reiner, editor, Kandolf, Reinhard, editor, and McManus, Bruce, editor
- Published
- 1993
- Full Text
- View/download PDF
8. Clinical application of antimyosin monoclonal antibody imaging in cardiology
- Author
-
Maddahi, Jamshid, Reiber, Johan H. C., editor, and Van Der Wall, Ernst E., editor
- Published
- 1992
- Full Text
- View/download PDF
9. What’s new in cardiac imaging?
- Author
-
Van Der Wall, Ernst E., van der Wall, Ernst E., editor, Sochor, Heinz, editor, Righetti, Alberto, editor, and Niemeyer, Menco G., editor
- Published
- 1992
- Full Text
- View/download PDF
10. What’s new in cardiac imaging
- Author
-
van der Wall, Ernst Evert and van der Wall, Ernst Evert
- Published
- 1992
- Full Text
- View/download PDF
11. ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model.
- Author
-
Verma, Daya D., Levchenko, Tatyana S., Bernstein, Eugene A., Mongayt, Dmitriy, and Torchilin, Vladimir P.
- Subjects
- *
ADENOSINE triphosphate , *LIPOSOMES , *MYOSIN , *MYOCARDIUM , *ISCHEMIA , *BLOOD circulation disorders , *LABORATORY rats - Abstract
Earlier demonstrated cardio-protection by ATP-loaded liposomes (ATP-L) was further improved by attachment of cardiac myosin-specific monoclonal 2G4 antibody onto the surface of ATP-L. ATP-IL were infused for 1 min duration before starting the global ischemia for 25 min followed by reperfusion for 30 min in an isolated rat heart. The left ventricular developed pressure at the end of reperfusion in ATP-IL group significantly recovered to above 80% of the baseline compared to ca 25% in the Kreb's-Henseleit (KH) buffer, ca 60% in the IL, and ca 70% in the ATP-L treated groups. At the end of the reperfusion, left ventricular end diastolic pressure significantly reduced to 15 ± 2 mmHg in ATP-IL group compared to 59 ± 6 mmHg in the KH buffer, 31 ± 4 mmHg in the IL and 23 ± 3 mmHg in the ATP-L controls. The extent of preservation depended on the amount of the antibody present on the surface of the ATP-IL. [ABSTRACT FROM AUTHOR]
- Published
- 2006
- Full Text
- View/download PDF
12. Indium 111 antimyosin and Tc-99m glucaric acid for noninvasive identification of oncotic and apoptotic myocardial necrosis.
- Author
-
Khaw, Ban-An, Silva, Jose, Petrov, Artiom, Hartner, William, and Silva, Jose Da
- Abstract
Background: Noninvasive imaging techniques would be highly desirable to differentiate oncotic from apoptotic cell death. Indium 111 antimyosin and technetium 99m glucaric acid were used to assess whether apoptotic and oncotic myocardial cell death can be differentiated.Methods and Results: Cultured H9C2 rat embryonic cardiocytes and CD1 rats were treated with doxorubicin to induce myocardial apoptosis. Acute myocardial oncosis was induced by heat or subcutaneous isoproterenol administration. Scanning electron microscopy, DNA laddering, TUNEL staining, In-111 antimyosin antibody, and Tc-99m glucaric acid were used to demonstrate in vitro and in vivo doxorubicin-induced apoptosis or isoproterenol-induced myocardial oncosis. Scanning electron microscopy, DNA laddering, and TUNEL staining of H9C2 cardiocytes treated with doxorubicin all showed cell death by apoptosis. Rat hearts treated with doxorubicin (10 and 20 mg/kg) were DNA ladder-positive and localized significantly greater In-111 antimyosin antibody (mean +/- SD, 0.1942 +/- 0.0150 percent injected dose per gram [%ID/g] and 0.1825 +/- 0.0238 %ID/g, respectively) than normal hearts (0.1154 +/- 0.0270 %ID/g, P <.05). No increase in myocardial Tc-99m glucaric acid activity was observed in rat hearts after 6, 12, and 24 hours of doxorubicin injection (0.0311 +/- 0.0066 %ID/g, 0.0356 +/- 0.007 %ID/g, and 0.0368 +/- 0.0047 %ID/g, respectively; control hearts, 0.0352 +/- 0.0099 %ID/g; P = not significant). Tc-99m glucaric acid uptake was significantly greater in isoproterenol-induced oncotic hearts (0.1256 +/- 0.1023 %ID/g) than in controls (P <.0001).Conclusions: Tc-99m glucaric acid is avid only for the oncotic myocardium. Antimyosin, on the other hand, is positive for both oncotic and apoptotic myocardium. [ABSTRACT FROM AUTHOR]- Published
- 2002
- Full Text
- View/download PDF
13. Complementary roles of antibody affinity and specificity for in vivo diagnostic cardiovascular targeting: how specific is antimyosin for irreversible myocardial damage?
- Author
-
Khaw, Ban-An, Petrov, Artiom, Narula, Jagat, Khaw, B A, Petrov, A, and Narula, J
- Subjects
ANIMAL experimentation ,ANTIGEN-antibody reactions ,COMPARATIVE studies ,DOGS ,HEART ,IMMUNITY ,IMMUNOGLOBULINS ,RESEARCH methodology ,MEDICAL cooperation ,MONOCLONAL antibodies ,MYOCARDIAL infarction ,MYOSIN ,RADIONUCLIDE imaging ,RADIOISOTOPES ,RADIOPHARMACEUTICALS ,REPERFUSION injury ,RESEARCH ,THALLIUM isotopes ,EVALUATION research ,CHELATING agents ,IODINE radioisotopes - Abstract
Background: Identification of irreversible myocyte injury with antimyosin antibody imaging depends on both antibody specificity and affinity. To characterize the role of antibody affinity, we performed studies in dogs with acute coronary occlusion followed by reperfusion using 3 monoclonal antimyosin antibodies with different affinities.Methods and Results: Dogs with experimental reperfused acute myocardial infarction were injected with 2 high-affinity radiolabeled monoclonal antimyosin Fab fragments (R11D10 and 2G42D7), 1 low-affinity antimyosin Fab (3H31E6), and a nonspecific Fab. The left lateral gamma images at 5 H were used to assess the infarct (I) to blood (B) region of interest (ROI) count density ratios by computer planimetry. All infarcts were confirmed by in vivo imaging with 201Tl for perfusion defects as well as by postmortem histochemical staining. The mean I/B ROI (+/-standard deviation [SD]) for R11D10 (1.701+/-0.376) was not significantly different from that of 2G42D7 (1.501+/-0.267, P = NS), but both were significantly greater than that of 3H31E6 Fab (0.85+/-0.12, P = .0001 and .0012, respectively). The I/B ROI of 3H31E6 Fab was similar to that of nonspecific Fab (0.75 to 0.77 range). Radiolabeled R11D10 and 2G42D7 were unequivocally positive by gamma imaging in all infarcts by 5 H. No infarcts were visualized with 3H31E6 or nonspecific Fab.Conclusions: The low-affinity antibody, despite its specificity for cardiac myosin, cannot be used to image the infarct zone. Therefore immunoscintigraphic diagnosis of irreversible myocardial injury with radiolabeled antimyosin Fab is doubly specific because in vivo visualization required both specificity and high enough affinity of the antibody. [ABSTRACT FROM AUTHOR]- Published
- 1999
- Full Text
- View/download PDF
14. Antimyosin scintigraphy in patients with acquired and hereditary muscular disorders.
- Author
-
Löfberg, M., Liewendahl, K., Savolainen, S., Nikkinen, P., Lamminen, A., Tiula, E., and Someri, H.
- Abstract
Scintigraphy with indium-111 labelled antimyosin has an established role in the evaluation of cardiac muscle damage. This antibody has been shown to cross-react with myosin in skeletal muscle. We therefore studied the usefulness of this method for the detection of skeletal muscle lesions in rhabdomyolysis, myositis and hereditary muscular dystrophies. All nine patients with rhabdomyolysis had focal uptake of antimyosin antibody which correlated with the clinical findings of soft tissue damage. However, a number of symptomless lesions were also detected by immunoscintigraphy. In rhabdomyolysis the target to non-target uptake ratios varied from 1.3 to 7.6. Diffuse uptake of antibody in skeletal muscle was observed in all three patients with polymyositis-dermatomyositis and in 12 out of 13 patients with muscular dystrophies. In myositis the intensity of antibody accumulation correlated reasonably well with the magnitude of oedema detected by magnetic resonance imaging (MRI). Most patients with Becker type or non-X-chromosomal muscular dystrophies showed slight or moderate uptake of antibody, mainly in the lower extremities. In these patients more antibody accumulated in the calves than in the thighs, whereas the findings on MRI were more prominent in the thighs than in the calves, presumably because of the better preserved muscle bulk in the calves. We conclude that antimyosin scintigraphy can be used for the detection of muscle lesions not only in acquired muscle diseases but also in hereditary muscular disorders, and that immunoscintigraphy provides information on muscle disease activity not obtainable with MRI. [ABSTRACT FROM AUTHOR]
- Published
- 1994
- Full Text
- View/download PDF
15. Correlations of antimyosin accumulation and histological manifestation of myocyte necrosis at different stages of idiopathic cardiomyopathy.
- Author
-
NAKATA, T., TSUDA, T., and IIMURA, O.
- Abstract
Although antimyosin uptake has been demonstrated in idiopathic cardiomyopathy, discrepancies between antimyosin positivity and histological examinations using biopsy speciments have been found. In order to investigate the correlations between antimyosin localization and histopathological alterations, the magnitude and distribution of antimyosin uptake were quantitatively assessed in aged-matched control (F1b) and hereditary idiopathic cardiomyopathy (Bio 14.6) hamsters at three different ages. In these studies, gamma counting and macroautoradiography were compared with histological alterations. Myocardial activities and percent areas of antomyosin uptake were significantly (<0⋅05) greater in 10-, 20-, and 30-week old Bio groups than in their respective control groups. Autoradiogrwns showed that antimyosin antibody was relatively localized, massive, and scattered in 10-week-old, 20-week-old and 30-week-old Bio hamsters, respectively. Histopathology demonstrated asitimyosin positivity not only in necrotic myocytes and accompanying calcium deposits but also in tissues showing inflammatory reactions but no histologically identifiable myocyte necrosis. In conclusion, antimyosin uptake seen in tissues with age-related disease processes did not necessarily correspond to histologically verified myocyte necrosis in the cardiomyopathy hearts, suggesting that antimyosin positivity reflects myocytes which show impaired sarcolemmal integrity but have not yet undergone myolysis. [ABSTRACT FROM PUBLISHER]
- Published
- 1995
- Full Text
- View/download PDF
16. Myocardial indium-111 antimyosin uptake in patients with idiopathic dilated cardiomyopathy: its relation to haemodynamics, histomorphometry, myocardial enteroviral infection, and clinical course.
- Author
-
WERNER, G. S., FIGULLA, H. R., MUNZ, D. L., KLINGEL, K., KANDOLF, R., EMRICH, D., and KREUZER, H.
- Abstract
The myocardial uptake of indium-111 antimyosin indicates the presence of ongoing myocyte damage. To evaluate the role of this finding in patients with idiopathic dilated cardiomyopathy (IDC), 36 patients were studied by planar and SPECT antimyosin imaging. The diagnosis of IDC was based on coronary angiography and left ventricular endomyocardial biopsy. The antimyosin scan was evaluated qualitatively from SPECT images and assessed quantitatively by a count density index (CDI) which measured the tracer activity over the heart relative to the lung and sternal region (normal value less than 1.20). Group 1 consisted of 13 patients (36%) with an increased myocardial antimyosin uptake, while 23 patients had a normal antimyosin scan (group 2). Clinical data, pulmonary artery pressures, gated blood pool ejection fraction and histomorphometry of endomyocardial biopsies were similar in both groups. During a follow-up of 21 ± 12 months there were two cardiac deaths in group 1 and 10 deaths in group 2 (P=0.12). The 2-year survival rate was 81% and 59%, respectively. During follow-up, there was no significant change in haemodynamic parameters in either group, but there was a slight improvement in functional NYHA class in group I (P < 0.05). No association was found between the presence of myocardial enterovirus infection, determined in 17 patients by in situ hybridization and the antimyosin scan ( = 0.5 g). Myocardial antimyosin uptake was found in a high percentage of patients with IDC, indicating ongoing myocyte damage. This finding was not related to any clinical, haemodynamic, morphological parameter, or enterovirus infection. Myocyte damage is a distinct feature in a subgroup of patients with IDC unrelated to any known causes of myocellular destruction. This subgroup showed a trend towards a more favourable clinical outcome. [ABSTRACT FROM PUBLISHER]
- Published
- 1993
- Full Text
- View/download PDF
17. Effect of hypoxia and reoxygenation on the isolated rabbit heart determined by monoclonal antimyosin antibody uptake.
- Author
-
Kilgore, Kenneth S and Lucchesi, Benedict R
- Abstract
Objective: The aim was to examine the effect of hypoxia and reoxygenation upon the isolated rabbit heart, and to determine whether or not irreversible tissue injury develops in association with the reintroduction of molecular oxygen to the previously hypoxic heart. Methods: Isolated rabbit hearts suspended on a Langendorff apparatus and perfused with a modified Krebs-Henseleit buffer were subjected to either 5 or 30 min hypoxia and, when applicable, followed by 45 min reoxygenation. The effect of hypoxia and reoxygenation upon the isolated heart was determined with a 125labelled monoclonal antibody to the intracellular protein myosin. Determination of tissue creatine kinase release and morphological analysis, using lanthanum chloride as a marker of vessel damage, were also performed to document the uptake of antimyosin with myocardial tissue injury. Results: Hearts subjected to 30 min hypoxia followed by 45 min reoxygenation snowed a significant increase in antimyosin uptake when compared to hearts exposed to 30 min hypoxia. Creatine kinase release and morphological analysis showed an increase in intracellular damage in hearts receiving 30 min hypoxia and 45 min reoxygenation when compared to hearts receiving 30 min hypoxia without subsequent reoxygenation. Hearts subjected to 5 min hypoxia followed by reoxygenation did not show a significant increase in antimyosin uptake as compared to continuously oxygenated control hearts or hearts made hypoxic for 5 min without subsequent reoxygenation. Conclusions: Antimyosin antibody binding increased in hearts subjected to hypoxia and reoxygenation compared to hearts subjected to hypoxia without reoxygenation. The data provide compelling evidence that reoxygenation of hypoxic tissue exacerbates the extension of cellular damage. The ability of superoxide dismutase and catalase to decrease antimyosin uptake suggests that reactive oxygen species play a role in reoxygenation induced myocardial damage. This study also provides evidence that the labelled antimyosin antibody provides a convenient approach to quantitate the extent of damage induced by hypoxia with and without subsequent reoxygenation.Cardiovascular Research 1993;27:1260-1267 [ABSTRACT FROM PUBLISHER]
- Published
- 1993
18. Antimyosin antibody imaging in experimental aortic regurgitation.
- Author
-
Lu, Ping, Zanzonico, Pat, Goldfine, Steven, Hardoff, Ruth, Magid, Norman, Gentile, Raffaele, Herrold, Edmund, Borer, Jeffrey, and Morgan, Mark
- Abstract
Fiber dropout and myocyte necrosis precede heart failure in experimental aortic regurgitation (AR). The current study aimed to determine whether this process can be detected by noninvasive scintigraphic imaging.
111 In-labeled antimyosin antibody Fab fragment (1 to 1.5 mCi) (Myoscint) was administered to each of 34 New Zealand White rabbits: 11 early (3 to 5 weeks) after surgical AR induction; 9 late (98 to 128 weeks) after AR induction; 5 normal and 3 sham-operated age-matched with early AR; and 3 normal and 3 sham-operated age-matched with late AR. Echocardiographic fractional shortening was indistinguishable among control, early AR, and late AR groups. In vivo gamma camera imaging 24 and 48 hours after isotope administration, post-mortem heart activity determination (percentage injected dose per gram), and autoradiography were performed. At 24 and 48 hours, heart-to-lung counts-per-pixel ratios from in vivo images were greater ( p<0.05) in the late AR rabbits than in each of the three other groups. No significant differences were found when early AR and older or younger control rabbits were compared. Heart activity (percentage injected dose per gram) in late AR rabbits trended toward higher values than in age-matched control rabbits ( p=0.057), but in early AR it was indistinguishable from that in the corresponding control ( p=0.413, difference not significant). The autoradiographic endocardial/epicardial activity ratio in late AR rabbits was greater than in control and early AR rabbits (1.27±0.13 vs 1.06±0.09 and vs 1.13±0.10, respectively, p<0.02). Whereas isotope uptake in late AR rabbits differed from that in control and early AR rabbits, systolic function was indistinguishable. Thus111 In-labeled antimyosin antibody imaging may permit noninvasive detection of AR-induced myocardial damage before functional deterioration. [ABSTRACT FROM AUTHOR]- Published
- 1997
- Full Text
- View/download PDF
19. Antibody imaging in the evaluation of cardiovascular diseases.
- Author
-
Khaw, Ban-An and Narula, Jagat
- Abstract
Antimyosin antibody was originally developed for in vivo detection of acute myocardial infarction. However, its utility has expanded to include diagnosis of various cardiovascular diseases in which myocyte necrosis constitutes an obligatory component of the disease. Thus antimyosin has also been used clinically for noninvasive diagnosis of acute myocarditis, heart transplant rejection, drug-induced cardiotoxicity, and other cardiomyopathies. This firstgeneration monoclonal antibody, antimyosin, has opened the way for the second-generation monoclonal antibodies such as antifibrin and antiplatelet for in vivo diagnostic use in the detection of deep venous thrombosis and pulmonary embolism and antiatherosclerotic lesion-specific antibody for diagnosis of metabolically active lesions. Whether the third generation of antibodies will include ultrasmall antigen-binding units or negative chargemodified antibodies must await future studies. [ABSTRACT FROM AUTHOR]
- Published
- 1994
- Full Text
- View/download PDF
20. Cytoskeletal and Cytocontractile Features of Myofibroblasts
- Author
-
Gabbiani, Giulio, Crawford, N., editor, and Taylor, D. E. M., editor
- Published
- 1986
- Full Text
- View/download PDF
21. 99mTc-annexin V and 111In-antimyosin antibody uptake in experimental myocardial infarction in rats
- Author
-
Jean-Baptiste Michel, Laure Sarda-Mantel, François Rouzet, Ban An Khaw, Florence Hervatin, Jean-Marc Vrigneaud, Dominique Le Guludec, Jean-Luc Vanderheyden, Liliane Louedec, Geneviève Martet, and Olivier Raguin
- Subjects
Male ,medicine.medical_specialty ,Pathology ,Metabolic Clearance Rate ,Myocardial Infarction ,Apoptosis ,Myosins ,chemistry.chemical_compound ,Annexin ,Internal medicine ,medicine ,Animals ,Myocyte ,Tissue Distribution ,Radiology, Nuclear Medicine and imaging ,Myocardial infarction ,Annexin A5 ,Rats, Wistar ,Radionuclide Imaging ,biology ,Chemistry ,Myocardium ,Antimyosin antibody ,Indium Radioisotopes ,Antibodies, Monoclonal ,Heart ,Organotechnetium Compounds ,General Medicine ,Phosphatidylserine ,medicine.disease ,Rats ,biology.protein ,Cardiology ,Immunohistochemistry ,Radiopharmaceuticals ,Antibody - Abstract
(99m)Tc-annexin V (ANX) allows scintigraphic detection of apoptotic cells via specific binding to exposed phosphatidylserine. In myocardial infarction, apoptosis of myocytes is variable and depends especially on the presence or absence of coronary reperfusion. In this study, ANX uptake in non-reperfused experimental myocardial infarcts was compared with uptake of a marker of myocyte necrosis ((111)In-antimyosin antibodies, AM) and an immunohistochemical marker of apoptosis (Apostain).The left anterior coronary artery was ligated in 47 Wistar rats, which were then injected with ANX (n=20), AM (n=21) or both (n=6). Myocardial uptake of ANX and AM was determined at 2 h (n=14), 4 h (n=14) and 24 h (n=19) after coronary ligation (CL), by quantitative autoradiography with (n=23) or without (n=24) gamma imaging. Heart-to-lung ratios (HLRs) and infarct-to-remote myocardium activity ratios (INRs) were calculated on the scintigrams and autoradiograms respectively. Cardiac sections were stained with haematoxylin-eosin and Apostain. The above studies were repeated in 12 normal rats.All rats with CL showed increased ANX and AM uptake in cardiac areas on scintigrams 24 h after CL, with HLRs higher than in controls: 3.1+/-0.6 versus 1.5+/-0.3 (p=0.001) for ANX and 1.99+/-0.44 versus 1.01+/-0.05 (p0.0005) for AM. Autoradiography showed intense ANX and AM uptake in infarcts, with comparable topography and INRs at 2 h, 4 h and 24 h after CL (4.6+/-0.9 versus 5.0+/-1.8 at 24 h), while Apostain staining was very low (0.06+/-0.06% of cells).In this model of persistent CL, we observed increased ANX uptake in injured myocardium, comparable in intensity, topography and kinetics to that of AM. There was only minimal Apostain staining in the same areas.
- Published
- 2005
22. Estimation of myocardial damage in Kawasaki disease using antimyosin antibody
- Author
-
Yoshihiro Yuasa, Yukiharu Kono, Shozo Oku, Masao Yoshinaga, Yuichi Nomura, and Takashi Noda
- Subjects
Adult ,Male ,medicine.medical_specialty ,Mucocutaneous Lymph Node Syndrome ,Myosins ,Gastroenterology ,Antibodies ,Electrocardiography ,Internal medicine ,parasitic diseases ,medicine ,Humans ,In patient ,Child ,Retrospective Studies ,business.industry ,Incidence ,Incidence (epidemiology) ,Antimyosin antibody ,Gamma globulin ,Retrospective cohort study ,medicine.disease ,Titer ,medicine.anatomical_structure ,Pediatrics, Perinatology and Child Health ,Immunology ,Female ,Kawasaki disease ,gamma-Globulins ,Cardiomyopathies ,business ,Artery - Abstract
In a retrospective study, 121 children with Kawasaki disease (KD) were investigated to determine (i) the incidence of myocardial damage using the antimyosin antibody (AMA) titer; (ii) the differences in the electrocardiograms between the AMA-positive and -negative patients; and (iii) the effect of treatment with intravenous gamma globulin (IVGG) on the AMA. Comparisons were made with 117 normal children (controls). Patients with KD showed a significantly higher mean AMA titer and more patients were positive for AMA than the controls. The AMA titer in the KD group was not related to the presence of coronary artery lesions. Electrocardiograms obtained during the acute and the convalescent stage of KD revealed that patients positive for AMA had a significantly lower voltage of T wave in lead V6 at week four than at week two of illness, whereas patients negative for AMA showed no T wave change after week two. The group treated with IVGG showed a significantly lower AMA titer than that not given IVGG. These observations suggest that myocardial damage occurs in some patients with KD which is unrelated to the presence of coronary artery lesions and that the treatment with IVGG reduces the AMA titer in patients with KD.
- Published
- 1993
23. 99mTc-antimyosin antibody imaging for the detection of acute myocardial infarction in human beings
- Author
-
Shoumo Bhattacharya, Jeffrey A. Leppo, Pete Manspeaker, X. J. Liu, Roxy Senior, and Avijit Lahiri
- Subjects
Male ,Time Factors ,Blood pool ,Group ii ,Myocardial Infarction ,chemistry.chemical_element ,Myosins ,Technetium ,Organometallic Compounds ,Humans ,Medicine ,Myocardial infarction ,Wall motion ,Aged ,Plasma clearance ,Chi-Square Distribution ,business.industry ,Antimyosin antibody ,Indium Radioisotopes ,Antibodies, Monoclonal ,Gated Blood-Pool Imaging ,Heart ,Organotechnetium Compounds ,Middle Aged ,medicine.disease ,chemistry ,Isotope Labeling ,Regression Analysis ,Female ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine ,Technetium-99m ,Half-Life - Abstract
111In-antimyosin imaging is a highly sensitive and specific technique for the detection of myocardial necrosis. Two new methods of labeling antimyosin with 99mTc have been developed, and were compared with the standard 111In-antimyosin imaging technique in 29 patients with acute myocardial infarction. Fourteen patients (group I) received directly labeled 99mTc-antimyosin, and 15 (group II) were given RP-1 conjugated 99mTc-antimyosin. 99mTc-antimyosin imaging was performed at 6, 12, and 24 hours, and 111In-antimyosin imaging was done at 24 and 48 hours following injection. The images were interpreted by three blinded observers. In group I, 99mTc-antimyosin uptake could be detected in 3, 6, and 12 cases at 6, 12, and 24 hours, respectively, compared with only 8 cases at 24 hours with 111In-antimyosin. At 48 hours all patients showed 111In-antimyosin uptake. In group II, 99mTc-antimyosin uptake could be detected in 2, 3, and 6 cases at 6, 12, and 24 hours, respectively, compared with 8 and 12 cases at 24 and 48 hours, respectively, with 111In-antimyosin. Gated blood pool studies could be obtained in all patients following 99mTc-antimyosin injection and could be used to identify regional wall motion abnormalities. The plasma half-lives of 99mTc-antimyosin in group I and group II were 2.67 ± 0.3 hours and 4.23 ± 0.3 hours, respectively, and the plasma half-life of 111In-antimyosin was 6.3 ± 0.4 hours. In this preliminary study, direct labeled 99mTc-antimyosin was at least as efficacious as earlier diagnostic techniques, had better imaging characteristics, and showed more rapid plasma clearance when compared with the standard 111In-antimyosin technique.
- Published
- 1993
24. Mechanism and Significance of Myocardial Uptake of Antimyosin Antibody in Myocarditis and Cardiomyopathy: Clinical and Experimental Studies
- Author
-
Junji Konishi, Nagara Tamaki, Akira Yoshida, Shigeru Morishima, Takehiko Yamada, Yoshiharu Yonekura, Chuichi Kawai, T. Ohkusa, Yuji Watanabe, Akira Matsumori, and Keigo Endo
- Subjects
Adult ,Cardiomyopathy, Dilated ,Male ,Pathology ,medicine.medical_specialty ,Myocarditis ,Heart disease ,Immunology ,Cardiomyopathy ,Myosins ,Contractile protein ,Pathology and Forensic Medicine ,Mice ,Animal model ,Enterovirus Infections ,medicine ,Animals ,Humans ,Immunology and Allergy ,Encephalomyocarditis virus ,Radionuclide Imaging ,Aged ,Autoantibodies ,Mice, Inbred BALB C ,Mechanism (biology) ,business.industry ,Antimyosin antibody ,Autoantibody ,Middle Aged ,medicine.disease ,Female ,business - Published
- 1993
25. Quantitative111in antimyosin antibody imaging to predict the age of myocardial infarction
- Author
-
Shoumo Bhattacharya, R. Senior, Xiu jie Liu, Avijit Lahiri, and D Jain
- Subjects
Time Factors ,Myocardial Infarction ,Infarction ,Myosins ,Electrocardiography ,Immunoglobulin Fab Fragments ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,cardiovascular diseases ,Myocardial infarction ,Radionuclide Imaging ,Lung ,Cardiac imaging ,business.industry ,Antimyosin antibody ,Indium Radioisotopes ,Antibodies, Monoclonal ,Heart ,medicine.disease ,Coronary heart disease ,Age estimation ,cardiovascular system ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine - Abstract
To establish whether quantitative 111In antimyosin uptake can be used to predict infarct age, we studied the heart-lung ratio in 107 images from 90 patients at various intervals following a Q-wave infarction. Imaging was performed 24 hours following 111In antimyosin injection. The HLR was measured as the ratio of the maximum counts in the infarcted myocardium to the adjacent lung background. The ratio ranged from 1.26 to 3.87, and declined with increasing infarct age. Infarcts were classified on the basis of age as type I (less than 3 days old), type II (less than 14 days), and type III (less than 90 days). True positive and false positive rates (TPR and FPR), and test-likelihood ratio calculations were performed for HLR thresholds ranging from 1 to 4, for the three infarct types. A FPR of 0% and likelihood ratio of infinity was obtained at a HLR threshold of 2.3 for type I infarcts (TPR 40.8%); at a HLR threshold of 2 for type II infarcts (TPR 50.6%), and a threshold of 1.8 for type III infarcts (TPR 52.6%). The likelihood of each infarct type can be estimated directly from the HLR for values below the above thresholds. These results show that quantitative 111In-antimyosin imaging may be used to predict infarct age.
- Published
- 1992
26. Clinical application of Indium-111 antimyosin antibody and Thallium-201 dual nuclide single photon emission computed tomography in acute myocardial infarction
- Author
-
Kazuyuki Sakata, Tsuneo Kaburagi, Mamoru Mochizuki, Takahumi Ishida, Yasunori Matsumoto, Hiroshi Yoshida, Tadao Miyamoto, Tsuneo Hoshino, Mari Kainouchi, Mitsuru Takezawa, and Shoichi Yokoyama
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Myocardial Infarction ,chemistry.chemical_element ,Infarction ,Single-photon emission computed tomography ,Revascularization ,Organometallic Compounds ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,cardiovascular diseases ,Inferior infarction ,Myocardial infarction ,Aged ,Tomography, Emission-Computed, Single-Photon ,medicine.diagnostic_test ,business.industry ,Antimyosin antibody ,Indium Radioisotopes ,Antibodies, Monoclonal ,General Medicine ,Middle Aged ,medicine.disease ,Thallium Radioisotopes ,chemistry ,cardiovascular system ,Thallium ,Female ,Radiology ,business ,Nuclear medicine ,Intracoronary thrombolysis - Abstract
The significance of indium-111 antimyosin antibody and thallium-201 dual nuclide single photon emission computed tomography (SPECT) was evaluated in 7 patients with acute myocardial infarction (AMI) who underwent emergency coronary angiography with successful revascularization by intracoronary thrombolysis. Indium-111 antimyosin antibody and thallium-201 dual nuclide SPECT was performed 11 to 36 days after the onset of AMI. Antimyosin SPECT images delineated areas of myocardial necrosis in all 7 patients (100%), but planar images detected necrotic areas in only 4 of 7 patients (57%). Peak CPK-MBs of the 3 patients in which no necrotic area was detected by indium-111 planar image showed a tendency to be smaller. Indium-111 antimyosin antibody/thallium-201 overlap was observed in all patients. The area of overlap was at the center of necrosis in 4 patients (2 anterior infarction, 1 inferior infarction, 1 inferolateral infarction) and at the peripheral portion in 3 patients (all 3 had inferior infarction). Indium-111 antimyosin antibody and thallium-201 dual nuclide SPECT is useful in identifying the localization of myocardial infarction and the overlap of these tracers might reflect the presence of salvaged myocardium adjacent to the necrotic myocardium.
- Published
- 1991
27. 111 In—antimyosin antibody imaging for detection of myocardial infarction
- Author
-
Avijit Lahiri, R. Senior, X. J. Liu, D Jain, and Paul Broadhurst
- Subjects
Male ,medicine.medical_specialty ,Myocardial Infarction ,Ischemia ,Myosins ,Mice ,Internal medicine ,medicine ,Animals ,Humans ,Radiology, Nuclear Medicine and imaging ,Myocardial infarction ,Radionuclide Imaging ,Prospective cohort study ,Ejection fraction ,Lung ,biology ,Unstable angina ,business.industry ,Antimyosin antibody ,Indium Radioisotopes ,Antibodies, Monoclonal ,General Medicine ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,Cardiology ,biology.protein ,Female ,Creatine kinase ,business - Abstract
Indium-111-antimyosin imaging has been shown to be a sensitive and specific method for detecting myocardial necrosis, but a quantitative method for interpretation of 111In-antimyosin planar images is lacking. A prospective study was performed in 114 patients with suspected acute myocardial infarction using planar 111In-antimyosin imaging. A ratio of maximum myocardial uptake counts (H) (9 X 9 pixels) over adjacent lung background (L), i.e. H/L ratio, was obtained from 24 and 48 h images. This value was compared with peak creatine kinase (CK) enzyme and left ventricular ejection fraction (LVEF). The patients were classified into groups based upon standard criteria for Q-wave acute myocardial infarction (Q-MI) (n = 50), non-Q-MI (n = 21), unstable angina (n = 15) and those with no evidence of MI or ischaemia (n = 28). The mean +/- S.D. H/L ratio in the Q-MI group was 2.28 +/- 0.50 (24 h, left anterior oblique, LAO, view) and was greater than the non-Q-MI group (1.98 +2- 0.30) (P less than 0.02). In patients with unstable angina (UA), seven had a high ratio (1.75 +/- 0.29) and eight had a lower ratio (1.29 +/- 0.07). In the group of patients without MI or UA, the ratio was 1.24 +/- 0.11 and this was significantly lower than the Q-MI and non-Q-MI groups and those patients with UA and positive 111In uptake (P less than 0.001, respectively). However, there was no significant difference between old MI and patients without evidence of MI or UA.(ABSTRACT TRUNCATED AT 250 WORDS)
- Published
- 1990
28. ATP-loaded immunoliposomes specific for cardiac myosin provide improved protection of the mechanical functions of myocardium from global ischemia in an isolated rat heart model
- Author
-
Dmitriy Mongayt, Eugene A. Bernstein, Tatyana S. Levchenko, Vladimir P. Torchilin, and Daya D. Verma
- Subjects
medicine.medical_specialty ,Cardiotonic Agents ,Ischemia ,Myocardial Ischemia ,Pharmaceutical Science ,Myocardial Reperfusion ,Myocardial Reperfusion Injury ,In Vitro Techniques ,Ventricular Function, Left ,Adenosine Triphosphate ,Pharmaceutical technology ,Internal medicine ,medicine ,Animals ,Particle Size ,business.industry ,Antimyosin antibody ,Myocardium ,Cardiac myosin ,Antibodies, Monoclonal ,Rat heart ,medicine.disease ,Surgery ,Rats ,Liposomes ,Cardiology ,Ventricular pressure ,business ,Cardiac Myosins - Abstract
Earlier demonstrated cardio-protection by ATP-loaded liposomes (ATP-L) was further improved by attachment of cardiac myosin-specific monoclonal 2G4 antibody onto the surface of ATP-L. ATP-IL were infused for 1 min duration before starting the global ischemia for 25 min followed by reperfusion for 30 min in an isolated rat heart. The left ventricular developed pressure at the end of reperfusion in ATP-IL group significantly recovered to above 80% of the baseline compared to ca 25% in the Kreb's-Henseleit (KH) buffer, ca 60% in the IL, and ca 70% in the ATP-L treated groups. At the end of the reperfusion, left ventricular end diastolic pressure significantly reduced to 15 +/- 2 mmHg in ATP-IL group compared to 59 +/- 6 mmHg in the KH buffer, 31 +/- 4 mmHg in the IL and 23 +/- 3 mmHg in the ATP-L controls. The extent of preservation depended on the amount of the antibody present on the surface of the ATP-IL.
- Published
- 2006
29. Myocardial injury in chronic aortic regurgitation: related to wall stress
- Author
-
Edmund M. Herrold, Massimiliano Szulc, Steven M. Goldfine, Jeffrey S. Borer, N.M. Magid, Pat Zanzonico, and Ping Lu
- Subjects
medicine.medical_specialty ,business.industry ,Antimyosin antibody ,Uptake ratio ,Hemodynamics ,Shape transformation ,Regurgitation (circulation) ,Wall stress ,Internal medicine ,medicine ,Cardiology ,sense organs ,Myocyte injury ,business ,Spherical shape - Abstract
We have previously shown that left ventricular (LV) shape transformation (from ellipsoid toward spherical) may modulate abnormal myocardial wall stresses occurring as a result of chronic severe aortic regurgitation (AR). If so then the extent of spherical shape change in AR may be inversely related to myocyte injury. To test this hypothesis, we compared the endocardial/epicardial antimyosin antibody uptake ratio in hearts from rabbits with early-AR and late-AR and from controls. The endocardial/epicardial antimyosin antibody activity ratio was increased in ellipsoid shaped late-AR hearts (vs control, p
- Published
- 2002
30. Targeting the Pathological Myocardium
- Author
-
Ban-An Khaw
- Subjects
Oncotic pressure ,medicine.medical_specialty ,business.industry ,Antimyosin antibody ,Myocardial Disorder ,medicine.disease ,Diagnostic modalities ,High morbidity ,Internal medicine ,Myocardial cell ,Cardiology ,Medicine ,Myocardial infarction ,business ,Pathological - Abstract
The rationale for targeting the pathological myocardium is to enable development of better diagnostic modalities or to enhance therapeutic interventions. Since the heart is an end-differentiated organ that has no substantial regenerative properties, any injury to the heart could potentially lead to high morbidity and mortality. The causes of myocardial injury are varied. Acute myocardial infarction results in oncotic myocardial cell death, whereas cardiomyopathies are now believed to be associated primarily with apoptotic myocardial cell death. If these myocardial disorders can be targeted specifically for early diagnosis, then morbidity and mortality may be reduced and novel therapeutic interventions may result in decreasing the injury to the heart. This chapter will focus primarily on targeting the oncotic myocardium. Targeting the apoptotic myocardium will not be considered in detail, but an introduction to the latest advances will be provided.
- Published
- 2002
31. Indium-111-labelled antimyosin antibody imaging in a patient with cardiac sarcoidosis
- Author
-
W. H. Knapp, Harm Ohlmeier, and Anna Bentrup
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Systemic disease ,Sarcoidosis ,Scintigraphy ,Organometallic Compounds ,Humans ,Medicine ,Radiology, Nuclear Medicine and imaging ,Decompensation ,Radionuclide Imaging ,biology ,medicine.diagnostic_test ,business.industry ,Antimyosin antibody ,Indium Radioisotopes ,Antibodies, Monoclonal ,Heart ,General Medicine ,medicine.disease ,Etiology ,biology.protein ,Antibody ,Cardiomyopathies ,business ,Complication - Abstract
The aetiology of cardiac dysfunction caused by sarcoid granulomatous inflammation may be difficult to clarify, and the potential of imaging methods is limited. We report on a patient who presented with acute biventricular decompensation. Pulmonary sarcoidosis was confirmed after hospitalization. Four weeks after the initiation of corticosteroid treatment, scintigraphy with indium-111-labelled antimyosin antibody Fab fragments (AMAB) revealed distinct activity accumulation in major parts of the left ventricular wall (heart-lung ratio: 1.6) 72 h following injection. There may be a role for AMAB scintigraphy in the early detection of cardiac sarcoidosis.
- Published
- 1993
32. Algorithms for Management of Heart Transplant Rejection Based on Surveillance of Myocardial Damage by Antimyosin Antibody Imaging
- Author
-
Manel Ballester, Ignasi Carrió, and Jagat Narula
- Subjects
medicine.medical_specialty ,medicine.diagnostic_test ,business.industry ,Antimyosin antibody ,Sampling error ,Patient management ,Endomyocardial biopsy ,Transplantation ,Heart transplant rejection ,Allograft rejection ,Biopsy ,Medicine ,Radiology ,business - Abstract
Endomyocardial biopsy remains the only reliable diagnostic tool to detect acute allograft rejection (see Chapters 9,13)1–2. Biopsies are performed serially after transplantation, especially during the initial months. Immunosuppressive treatment is augmented when myocyte damage is detected by biopsy. Biopsy-based patient management is widely used and has been associated with very good long-term survival.3 However, there are significant limitations of endomyocardial biopsy. These include high procedural cost, a small but definite morbidity, and dwindling yield in obtaining adequate myocardial samples after the first year of transplantation. In addition, sampling error of the biopsy to detect acute rejection remains a major problem since myocardial expression of acute rejection is not a diffuse but rather a patchy. Rarely, patients who die of acute rejection demonstrate foci of myocardial damage and inflammation which can be seen surrounded by large areas of apparently intact myocardium.4,5
- Published
- 2001
33. Usefulness of antimyosin antibody imaging for the detection of active rheumatic myocarditis
- Author
-
Ban-An Khaw, Kolli Srinath Reddy, Manvir Bhatia, H W Strauss, Tsunehiro Yasuda, James F. Southern, Kewal K. Talwar, Jagat Narula, Prem Chopra, Atul Malhotra, Ramachandran S. Vasan, and Rajendra Tandon
- Subjects
Adult ,Male ,medicine.medical_specialty ,Pathology ,Myocarditis ,Heart disease ,Adolescent ,Myosins ,Scintigraphy ,Internal medicine ,Medicine ,Humans ,Child ,Radionuclide Imaging ,Rheumatic myocarditis ,medicine.diagnostic_test ,business.industry ,Antimyosin antibody ,Indium Radioisotopes ,Autoantibody ,Rheumatic Heart Disease ,Antibodies, Monoclonal ,medicine.disease ,Monoclonal ,Cardiology ,Rheumatic fever ,Female ,Cardiology and Cardiovascular Medicine ,business - Abstract
Myocarditis constitutes an important component of rheumatic carditis. Antimyosin scintigraphy, which allows noninvasive assessment of myocyte damage, can be used for documentation of cardiac involvement in patients with rheumatic fever where clinical diagnosis is not unequivocal.
- Published
- 1999
34. Imaging of acute myocardial infarction and reperfusion
- Author
-
Jesus A. Bianco, Richard J. Hammes, Michael F. Wilson, and Linda Sebree
- Subjects
medicine.medical_specialty ,Nuclear imaging ,Myocardial Infarction ,chemistry.chemical_element ,Myocardial Reperfusion Injury ,Technetium ,Internal medicine ,medicine ,Animals ,Humans ,Pharmacology (medical) ,cardiovascular diseases ,Myocardial infarction ,Radionuclide Imaging ,health care economics and organizations ,Fluorodeoxyglucose ,Radioisotopes ,business.industry ,Antimyosin antibody ,Electrocardiography in myocardial infarction ,99mTc Sestamibi ,medicine.disease ,chemistry ,Clinical diagnosis ,Cardiology ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
During the last 20 years there has been a large amount of investigation designed to determine what is the best way of imaging acute myocardial infarction (AMI) using radiopharmaceuticals. 99mTc pyrophosphate is ideal for cases where the clinical diagnosis cannot be made but it is insensitive to detect subendocardial AMI and is taken up by reversibly-injured myocytes. Antimyosin antibody imaging is specific for AMI but it is flow-dependent at low myocardial flows and it distributes in a nonuniform way in reperfused infarcts requiring high nuclear imaging (SPECT or PET) spatial resolution for proper measurement. 18F fluorodeoxyglucose (FDG) is taken up by viable cells but likely by macrophages too, in the core of AMI. 99mTc glucarate has not been investigated in detail but this sugar analog is more accurate than FDG in AMI. 99mTc sestamibi has been extensively used for AMI measurement but SPECT quantitation of transmural infarcts has not been achieved. Unresolved issue is imaging of AMI during reperfusion where there is widespread microvascular injury and capillary plugging.
- Published
- 1995
35. Recognition of Rhabdo- and Leiomyosarcomas by Means of in-111 Labeled Antimyosin-Antibody Fragments — An Improvement for the Oncologic Diagnostic
- Author
-
W.-G. Franke, S. Weiß, S. Wiener, E. Siegert, and K. Köhler
- Subjects
body regions ,Pathology ,medicine.medical_specialty ,Anatomical method ,business.industry ,Antimyosin antibody ,Medicine ,business ,medicine.disease ,Recurrent Leiomyosarcoma ,Primary tumor ,Histological examination - Abstract
10 patients suffering from myosarcomas have been studied with In-111 labeled antimyosin Fabs in our department until now. At all times the diagnosis was ascertained by histological examination of the primary tumor. All myosarcomas, ie rhabdomyosarcomas as well as leiomyosarcomas, and different histologically and histochemically identified subgroups were also detected by antimyosin radioimmunoscintigraphy except for one case of recurrent leiomyosarcoma. In some cases the tumors could be delineated more clearly than by means of MRT or other anatomical methods.
- Published
- 1995
36. Relationship between the degree of injury at operation and the change in antimyosin antibody titer in the postpericardiotomy syndrome
- Author
-
Y. Umebayashi, Masao Yoshinaga, Shozo Oku, Tsutomu Haraguchi, Koichiro Miyata, A. Taira, Yuichi Nomura, and Takashi Noda
- Subjects
Male ,medicine.medical_specialty ,Adolescent ,Myosins ,Antibodies ,Pericardial Effusion ,Internal medicine ,medicine ,Creatine kinase isoenzyme ,Postpericardiotomy Syndrome ,Humans ,Prospective Studies ,Cardiac Surgical Procedures ,Child ,Creatine Kinase ,business.industry ,Antimyosin antibody ,Cardiac myosin ,Postpericardiotomy syndrome ,Vascular surgery ,medicine.disease ,Surgery ,Cardiac surgery ,Isoenzymes ,Titer ,Effusion ,Child, Preschool ,Pediatrics, Perinatology and Child Health ,Cardiology ,Female ,Cardiology and Cardiovascular Medicine ,business ,Biomarkers - Abstract
Successive measurements of cardiac myosin light chain I (MLC), creatine kinase isoenzyme MB (CKMB), and the titer of antimyosin antibody (AMA) were performed prospectively in 19 patients following open heart surgery. Seven of these patients showed the postpericardiotomy syndrome (PPS). No differences in serum concentrations of MLC or CKMB were observed between the patients with and without PPS, and all patients in both groups had abnormal MLC values after surgery. However, only patients with PPS had significantly elevated AMA titers. The maximum AMA titer was significantly correlated with the severity of the effusion. These data suggest that PPS is unrelated to the severity of myocardial injury during operation. Furthermore, the AMA titer may be useful as one of the indicators for determining the patient's clinical condition.
- Published
- 1994
37. Myocardial uptake of antimyosin antibody compared with serum myosin light chain I levels in patients with myocardial infarction
- Author
-
Mitsuko Suehiro, Hitoshi Naruse, Tadaaki Iwasaki, and Minoru Fukuchi
- Subjects
Adult ,Male ,medicine.medical_specialty ,Myosin Light Chains ,Myocardial Infarction ,Myosins ,Scintigraphy ,Internal medicine ,Myosin ,Organometallic Compounds ,Medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,In patient ,Myocardial infarction ,Myosin light chain I ,Aged ,Hibernating myocardium ,Immunoradiometric assay ,medicine.diagnostic_test ,business.industry ,Antimyosin antibody ,Antibodies, Monoclonal ,General Medicine ,Middle Aged ,medicine.disease ,Endocrinology ,Immunology ,Female ,medicine.symptom ,business - Abstract
Myocardial accumulation of In-111-antimyosin (InAM) was evaluated in comparison with circulating serum myosin light chain I (LCI) level at the time of InAM injection. Seventeen consecutive patients were studied at various stages ranging from 6 days to 34 days after myocardial infarction (MI). The infarct area was positive for InAM uptake in all patients (100%), and significant myocardial uptake was observed in 14 patients (82.4%). The intensity of InAM uptake correlated with the infarct location shown by ECG and CAG. In contrast, 12 patients (70.6%) had normal or undetectable serum myosin LCI levels, with 5 being normal (0.42–2.5 ng/ml) and 7 undetectable (0.42 ng/ml or less). Only 5 patients (29.4%) had elevated serum myosin LCI levels at the time of InAM injection, and this elevation was slight, ranging from 3.4 to 4.5 ng/ml (mean: 3.75 ng/ml). Among patients with undetectable, normal, and elevated serum myosin LCI levels, there was no significant correlation between InAM uptake and the serum myosin LCI level. Thus, even after the serum myosin LCI level has decreased to normal, InAM can still bind to cardiac myosin in patients with MI, presumably until there is complete recovery from the hibernating myocardium due to ischemic damage.
- Published
- 1992
38. 111In antimyosin antibody uptake is related to the age of myocardial infarction
- Author
-
Shoumo Bhattacharya, Xiu-jie Liu, R. Senior, D Jain, Jeffrey A. Leppo, and Avijit Lahiri
- Subjects
Adult ,Male ,Time Factors ,Myocardial Infarction ,Infarction ,Myosins ,Chest pain ,QT interval ,Antibodies ,Electrocardiography ,medicine ,Humans ,Gamma Cameras ,Myocardial infarction ,Radionuclide Imaging ,Lung ,Aged ,medicine.diagnostic_test ,business.industry ,Antimyosin antibody ,Indium Radioisotopes ,Heart ,Middle Aged ,medicine.disease ,Intensity (physics) ,medicine.anatomical_structure ,Regression Analysis ,Female ,medicine.symptom ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine - Abstract
The intensity of 111In antimyosin uptake is related to the type (Q wave or non-Q wave), size, and location of an acute myocardial infarction. To determine whether the uptake intensity is also related to the infarct age, and to establish the time frame during which 111In antimyosin uptake occurs postinfarction, we studied a quantitative measure of uptake intensity, the heart-lung (HL) ratio, in 90 consecutive patients at various intervals following a Q wave infarction. Imaging was performed 24 hours following 111In antimyosin injection. Uptake of antimyosin could be demonstrated up to 154 days postinfarction. The HL ratio was measured as the ratio of the maximum counts in the infarcted myocardium to the adjacent lung background, and was 1.93 +/- 0.51 (mean +/- SD) overall. The ratio declined exponentially with increasing age of infarct. Using nonlinear regression analysis, 47% of the total variance of the HL ratio could be attributed to age alone (p less than 0.001). Sequential antimyosin imaging was performed in nine patients, with the first study between 4 and 15 days, the second between 50 to 100 days, and the third between 125 to 270 days after the onset of chest pain. The HL ratios were (mean +/- SD) 1.77 +/- 0.25 for scans between 4 and 15 days, 1.54 +/- 0.12 for scans between 50 and 100 days (p less than 0.02), and 1.42 +/- 0.16 (p less than 0.05) for scans between 125 to 270 days, further establishing the progressive reduction in 111In antimyosin uptake with age of myocardial infarction.
- Published
- 1991
39. Antimyosin antibodies in CNS-lupus
- Author
-
Takako Kawai, Takao Ohkubo, Kenji Tani, Kiyoshi Kato, and Keiichiro Matsunaga
- Subjects
Adult ,Male ,Cns lupus ,Human leukocyte antigen ,Myosins ,General Biochemistry, Genetics and Molecular Biology ,immune system diseases ,Central Nervous System Diseases ,parasitic diseases ,Medicine ,Humans ,Lupus Erythematosus, Systemic ,skin and connective tissue diseases ,Autoantibodies ,biology ,business.industry ,Antimyosin antibody ,HLA-B40 Antigen ,Healthy subjects ,Negativity effect ,General Medicine ,Middle Aged ,Immunity, Innate ,Titer ,Immunoglobulin M ,HLA-B Antigens ,Immunology ,biology.protein ,Female ,Antibody ,business - Abstract
MATSUNAGA, K., KAWAI, T., KATO, K., TANI, K. and OHKUBO, T. Antimyosin Antibodies in CNS-Lupus. Tohoku J. Exp. Med., 1991, 163 (3), 211-218 -Anti-myosin antibodies (AMA) in the sera of patients with systemic lupus erythematosus (SLE) and healthy subjects were measured by ELISA. AMA were IgM dominant. The titers of AMA were significantly higher in active SLE than in inactive SLE and healthy subjects. AMA negative SLE patients have significantly lower serum IgM than that in AMA positive subjects. Frequency analysis of HLA antigens in SLE revealed that AMA positivity was associated with HLA-A11, AMA negativity with HLA-B40 and DR2, and those with central nervous system involvement (CNS-SLE) were associated with HLA-B40. The patients with CNS-SLE have low serum IgM, low titer of AMA and HLA-B40.
- Published
- 1991
40. Antimyosin Antibody Imaging in Myocardial Infarction
- Author
-
A. Lahiri and S. Bhattacharya
- Subjects
medicine.medical_specialty ,Myocarditis ,medicine.diagnostic_test ,biology ,business.industry ,Antimyosin antibody ,Single-photon emission computed tomography ,medicine.disease ,Specific antibody ,Internal medicine ,medicine ,Cardiology ,biology.protein ,Myocardial necrosis ,Myocardial infarction diagnosis ,Myocardial infarction ,Antibody ,business - Abstract
Antimyosin (Myoscint ™ Centocor Inc. Malvern PA) is a Fab fragment of a specific antibody to myosin heavy chains that binds to necrotic cardiac myocytes. Planar or single photon emission computed tomography (SPECT) techniques using Indium- 111 labelled antibody have been used for the clinical detection of myocardial necrosis, both in acute myocardial infarction, and in myocarditis. This article reviews the role of antimyosin (AM) imaging in myocardial infarction diagnosis and risk stratification.
- Published
- 1991
41. Production of carrier-free 66Ga and labeling of antimyosin antibody for positron imaging of acute myocardial infarction
- Author
-
M Coene, Francis Colardyn, Guido Slegers, Jan A. Everaert, Patrick Goethals, Ignace Lemahieu, Dirk Vogelaers, and Guy R. Heyndrickx
- Subjects
medicine.drug_class ,Myocardial Infarction ,Gallium Radioisotopes ,Myosins ,Monoclonal antibody ,Positron ,Dogs ,Medicine ,Animals ,Radiology, Nuclear Medicine and imaging ,Myocardial infarction ,biology ,medicine.diagnostic_test ,business.industry ,Antimyosin antibody ,Radionuclide Generators ,Antibodies, Monoclonal ,General Medicine ,Pentetic Acid ,medicine.disease ,Positron emission tomography ,Isotope Labeling ,Monoclonal ,biology.protein ,Myocardial necrosis ,Antibody ,business ,Nuclear medicine ,Tomography, Emission-Computed - Abstract
A method for labeling monoclonal antimyosin antibodies with 66Ga is described. The radionuclide is a positron emitter (t1/2: 9.4h) produced by means of the 63Cu (4He, n) 66Ga reaction. Purification of the 66Ga from the copper target is described in detail. Monoclonal antimyosin antibodies are labeled with 66Ga at a high yield (99%) by transcomplexation from an acetate buffer with the diethylenetriamine pentaacetic acid (DTPA)-labeled antibody and preliminary evaluated in two dogs for imaging of myocardial necrosis by positron emission tomography.
- Published
- 1990
42. Acute diffuse myocyte necrosis evidenced with 111In-antimyosin antibody scintigraphy in a patient with aortic stenosis
- Author
-
Christiane Vissuzaine, Laure Sarda, Eric Brochet, Marc Faraggi, N Delahaye, and Dominique Le Guludec
- Subjects
medicine.medical_specialty ,Myosins ,Scintigraphy ,Myocyte necrosis ,Angina ,Necrosis ,Internal medicine ,parasitic diseases ,Organometallic Compounds ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,In patient ,Radionuclide Imaging ,Aged ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,Myocardium ,Antimyosin antibody ,Indium Radioisotopes ,Antibodies, Monoclonal ,Heart ,Aortic Valve Stenosis ,medicine.disease ,Stenosis ,Cardiology ,Female ,Myocardial necrosis ,Cardiology and Cardiovascular Medicine ,business ,Acute diffuse - Abstract
111In-AMA scintigraphy coupled with rest 201Tl imaging may be useful for the positive diagnosis of subacute myocardial necrosis in patients with angina, aortic stenosis, and normal coronary arteries. The present observation suggests that diffuse myocyte necrosis, histologically confirmed in this case, can be identified with 111In-AMA and may be a cause of cardiac complications in such patients.
- Published
- 1997
43. 99mTc-HYNIC-Annexin-V and 111In-Antimyosin-antibody myocardial uptake after permanent coronary ligature and ischemia-reperfusion in rats
- Author
-
Ban An Khaw, Michel Jb, Geneviève Martet, François Rouzet, Georges Saumon, Liliane Louedec, Laure Sarda-Mantel, O. Raguin, D. Le Guludec, and Jean-Marc Vrigneaud
- Subjects
medicine.medical_specialty ,business.industry ,Antimyosin antibody ,medicine.medical_treatment ,Ischemia ,medicine.disease ,Annexin ,Internal medicine ,Cardiology ,medicine ,Radiology, Nuclear Medicine and imaging ,Cardiology and Cardiovascular Medicine ,business ,Ligature - Published
- 2005
44. Acute diffuse myocyte necrosis evidenced with 111In-antimyosin antibody scintigraphy in a patient with aortic stenosis
- Author
-
Sarda, Laure, Faraggi, Marc, Brochet, Eric, Vissuzaine, Christiane, Delahaye, Nicolas, and Le Guludec, Dominique
- Published
- 1997
- Full Text
- View/download PDF
45. Radiolabeled antimyosin antibody as an index of fibrosis in aortic regurgitation
- Author
-
P Lu
- Subjects
medicine.medical_specialty ,Fibrosis ,business.industry ,Internal medicine ,Antimyosin antibody ,medicine ,Cardiology ,Radiology, Nuclear Medicine and imaging ,Radiology ,Regurgitation (circulation) ,Cardiology and Cardiovascular Medicine ,medicine.disease ,business - Published
- 1997
46. Specific myocardial involvement in systemic diseases assessed by indium111-antimyosin-antibody (AMA) and rest thallium spect
- Author
-
Doumit Daou, M.F Kahn, Elisabeth Palazzo, Marc Faraggi, Rachida Lebtahi, D Le Guludec, and L Sarda
- Subjects
business.industry ,Antimyosin antibody ,Medicine ,Radiology, Nuclear Medicine and imaging ,Thallium spect ,Cardiology and Cardiovascular Medicine ,business ,Nuclear medicine ,Rest (music) - Published
- 1997
47. Tc-99m antimyosin antibody (3–48) imaging for detection of acute myocardial infarction
- Author
-
A. Gagnon, Jean Grégoire, C. Benjamin, Raymond Lambert, Denis-Carl Phaneuf, Hôtel-Dieu de Montréal, H. Sikorska, L. Boucher, and Raymond Taillefer
- Subjects
medicine.medical_specialty ,business.industry ,Antimyosin antibody ,Internal medicine ,Cardiology ,Medicine ,Radiology, Nuclear Medicine and imaging ,Myocardial infarction ,Cardiology and Cardiovascular Medicine ,business ,medicine.disease - Published
- 1995
48. Distinction between physiologic and pathologic myocardial hypertrophy in athletes: Possible Role of 111In-antimyosin antibody studies
- Author
-
Antonio Bayés, Lluis Berná, Ignasi Carrió, Ricard Serra-Grima, Montserrat Estorch, and Maite Subirana
- Subjects
Pathology ,medicine.medical_specialty ,biology ,business.industry ,Athletes ,Myocardial hypertrophy ,Antimyosin antibody ,Medicine ,Radiology, Nuclear Medicine and imaging ,Cardiology and Cardiovascular Medicine ,business ,biology.organism_classification - Published
- 1995
49. Impaired function of mitochondria observed in situ in cardiomyocytes in diabetic rats
- Author
-
Toshiro Yamaguchi, Akira Matsumori, and Takehiko Yamada
- Subjects
medicine.medical_specialty ,Chronic stage ,Pathology ,business.industry ,Antimyosin antibody ,Infarction ,medicine.disease ,Internal medicine ,Cardiology ,Medicine ,Myocyte ,Immunohistochemistry ,Cardiology and Cardiovascular Medicine ,business ,Molecular Biology - Published
- 1992
50. Antimyosin antibody imaging in the diagnosis of acute myocarditis
- Author
-
G W Dec, Tsunehiro Yasuda, John T. Fallon, Herman K. Gold, Igor F. Palacios, Robert C. Leinbach, Edgar Haber, Ban-An Khaw, and H W Strauss
- Subjects
Pathology ,medicine.medical_specialty ,Acute myocarditis ,Myocarditis ,biology ,business.industry ,Antimyosin antibody ,biology.protein ,medicine ,Antibody ,Cardiology and Cardiovascular Medicine ,medicine.disease ,business - Published
- 1987
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.